See more : NEXTIN, Inc. (348210.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Piramal Enterprises Limited (PEL.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Piramal Enterprises Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- OTRS AG (TR9.DE) Income Statement Analysis – Financial Results
- JX Luxventure Limited (KBSF) Income Statement Analysis – Financial Results
- Adeshwar Meditex Limited (ADESHWAR.BO) Income Statement Analysis – Financial Results
- Ceenik Exports (India) Limited (CEENIK.BO) Income Statement Analysis – Financial Results
- LIC Housing Finance Limited (LICHSGFIN.NS) Income Statement Analysis – Financial Results
Piramal Enterprises Limited (PEL.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.piramal.com/businesses/piramal-enterprises/
About Piramal Enterprises Limited
Piramal Enterprises Limited operates in financial services and pharmaceuticals businesses in India, North America, Europe, Japan, and internationally. It operates through Pharmaceuticals Manufacturing and Services, and Financial Services segments. The company provides housing finance and other financing solutions, such as private equity, structured debt, senior secured debt, construction finance, and flexi lease rental discounting to real estate sector; and funding solutions to infrastructure, renewable energy, roads, industrials, auto components, and other sectors. It also operates distressed asset investing platform that invests in equity and/or debt in assets. In addition, the company offers contract development and manufacturing solutions, including drug discovery, production, and manufacturing of active pharmaceutical ingredients and formulations; and inhalation and injectable anaesthesia, injectable pain, antibiotics, and other medications, as well as intrathecal spasticity management drugs. Further, it provides over-the-counter products comprising analgesics, skin care, kids' wellness, digestives, women's health, disinfectant, Covifind, and hygiene and protection products, as well as vitamins, minerals, and supplements primarily under the Saridon, Lacto Calamine, Little's, I-Pill, Supradyn, Polycrol, Triactiv, Ourdaily, Pulse Oximeters, and Tetmosol brands. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is based in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.34B | 47.85B | 138.29B | 127.71B | 129.69B | 131.39B | 105.73B | 84.38B | 65.85B | 50.96B | 44.64B | 34.96B | 21.33B | 25.10B | 36.24B | 32.45B | 28.48B | 24.20B | 15.82B | 13.08B |
| Cost of Revenue | 29.00B | 180.90M | 28.36B | 36.56B | 18.86B | 17.41B | 16.98B | 15.46B | 14.80B | 14.30B | 12.55B | 11.52B | 10.23B | 10.42B | 14.22B | 12.79B | 10.83B | 9.00B | 5.90B | 6.25B |
| Gross Profit | 31.33B | 47.67B | 109.93B | 91.15B | 110.83B | 113.98B | 88.75B | 68.92B | 51.05B | 36.66B | 32.10B | 23.44B | 11.10B | 14.68B | 22.02B | 19.66B | 17.66B | 15.20B | 9.92B | 6.84B |
| Gross Profit Ratio | 51.93% | 99.62% | 79.49% | 71.37% | 85.46% | 86.75% | 83.94% | 81.68% | 77.53% | 71.94% | 71.90% | 67.05% | 52.02% | 58.49% | 60.76% | 60.58% | 61.99% | 62.81% | 62.72% | 52.26% |
| Research & Development | 0.00 | 1.48 | 1.28B | 793.10M | 719.60M | 2.11B | 2.05B | 2.05B | 2.50B | 3.68B | 3.92B | 2.87B | 2.33B | 716.20M | 701.50M | 848.80M | 805.50M | 1.26B | 775.30M | 495.40M |
| General & Administrative | 6.90B | 6.01B | 5.03B | 3.62B | 3.09B | 2.94B | 2.38B | 2.47B | 2.58B | 2.26B | 1.80B | 2.05B | 2.23B | 0.00 | 4.21B | 4.10B | 3.54B | 3.73B | 2.12B | 1.67B |
| Selling & Marketing | 973.40M | 484.90M | 3.12B | 2.23B | 2.01B | 1.77B | 1.98B | 2.27B | 2.00B | 2.20B | 2.08B | 1.32B | 1.21B | 0.00 | 2.85B | 2.32B | 1.66B | 1.39B | 1.15B | 1.33B |
| SG&A | 7.87B | 6.50B | 8.15B | 5.85B | 5.09B | 4.70B | 4.36B | 4.74B | 4.58B | 4.46B | 3.87B | 3.38B | 3.44B | 0.00 | 7.06B | 6.42B | 5.20B | 5.12B | 3.27B | 3.00B |
| Other Expenses | 0.00 | 519.10M | 3.69B | 1.25B | 1.16B | 1.17B | 370.70M | 461.40M | 135.20M | 54.20M | 18.60M | 300.00K | -257.70M | 9.53B | 8.08B | -1.08B | 7.05B | 4.32B | 4.19B | 1.84B |
| Operating Expenses | 14.71B | 3.34B | 43.97B | 21.86B | 51.60B | 47.14B | 41.89B | 37.67B | 35.22B | 30.40B | 28.11B | 21.17B | 12.15B | 10.25B | 15.84B | 6.19B | 13.05B | 10.71B | 8.24B | 5.33B |
| Cost & Expenses | 14.71B | 3.52B | 72.34B | 58.42B | 70.47B | 64.54B | 58.87B | 53.13B | 50.02B | 44.70B | 40.66B | 32.69B | 22.39B | 20.67B | 30.06B | 18.98B | 23.88B | 19.71B | 14.14B | 11.58B |
| Interest Income | 1.73B | 1.14B | 370.90M | 408.10M | 1.62B | 1.50B | 1.57B | 998.00M | 1.03B | 1.16B | 149.20M | 182.30M | 1.42B | 2.81B | 0.00 | 0.00 | 403.00M | 214.10M | 97.40M | 84.30M |
| Interest Expense | 27.24B | 7.12B | 44.80B | 40.89B | 50.63B | 42.98B | 29.23B | 20.01B | 9.26B | 4.56B | 7.93B | 4.83B | 2.15B | 1.00B | 1.84B | 0.00 | -60.10M | -91.00M | -75.60M | -107.80M |
| Depreciation & Amortization | 1.46B | 1.17B | 6.66B | 5.61B | 5.20B | 4.01B | 4.77B | 3.82B | 3.27B | 2.90B | 2.47B | 2.10B | 1.29B | 1.20B | 1.43B | 1.20B | 947.30M | 818.20M | 688.10M | 524.40M |
| EBITDA | -3.86B | 46.08B | 73.38B | 74.89B | 84.45B | 72.67B | 52.07B | 35.48B | 21.64B | 8.89B | 6.21B | 4.46B | -361.60M | 1.22B | 7.27B | 5.89B | 5.19B | 3.88B | 2.38B | 2.03B |
| EBITDA Ratio | -6.40% | 96.30% | 57.68% | 61.88% | 54.93% | 55.50% | 50.48% | 45.69% | 32.16% | 21.40% | 13.68% | 14.98% | 6.54% | 22.44% | 21.73% | 46.56% | 20.89% | 22.14% | 15.03% | 15.51% |
| Operating Income | 47.83B | 44.85B | 64.81B | 69.29B | 59.23B | 66.84B | 51.68B | 34.81B | 19.80B | 36.51B | 3.54B | 2.80B | 3.33B | 166.63B | 5.73B | 3.38B | 3.71B | 2.57B | 1.44B | 2.11B |
| Operating Income Ratio | 79.28% | 93.73% | 46.86% | 54.25% | 45.67% | 50.87% | 48.88% | 41.25% | 30.06% | 71.63% | 7.94% | 8.02% | 15.59% | 663.92% | 15.81% | 10.42% | 13.04% | 10.62% | 9.13% | 16.09% |
| Total Other Income/Expenses | -80.62B | 17.93B | -29.31B | -39.13B | -63.83B | -40.23B | -27.22B | -16.44B | -10.25B | -6.15B | -8.40B | -4.29B | 2.46B | 166.25B | -1.91B | -107.60M | 5.99B | 102.80M | 7.80M | 2.90M |
| Income Before Tax | -32.78B | 143.11B | 25.10B | 34.56B | 14.07B | 20.12B | 19.64B | 14.80B | 8.94B | 30.35B | -4.35B | -1.93B | 1.21B | 165.63B | 5.00B | 3.41B | 3.73B | 2.67B | 1.48B | 2.11B |
| Income Before Tax Ratio | -54.33% | 299.06% | 18.15% | 27.06% | 10.85% | 15.31% | 18.57% | 17.54% | 13.58% | 59.56% | -9.74% | -5.51% | 5.67% | 659.93% | 13.79% | 10.50% | 13.09% | 11.04% | 9.38% | 16.12% |
| Income Tax Expense | -15.95B | -224.00M | 5.11B | 20.43B | 19.60B | 8.61B | -28.76B | 2.28B | 1.03B | 3.45B | 627.50M | 247.60M | 56.30M | 36.80B | 910.80M | 219.40M | 376.60M | 388.90M | 238.10M | 464.80M |
| Net Income | -16.84B | 143.33B | 19.23B | 13.32B | 240.30M | 14.73B | 51.21B | 12.52B | 9.51B | 28.50B | -5.01B | -2.27B | 1.12B | 128.83B | 4.82B | 3.16B | 3.34B | 2.18B | 1.21B | 1.64B |
| Net Income Ratio | -27.90% | 299.53% | 13.91% | 10.43% | 0.19% | 11.21% | 48.44% | 14.84% | 14.44% | 55.92% | -11.23% | -6.50% | 5.23% | 513.31% | 13.30% | 9.75% | 11.72% | 9.01% | 7.62% | 12.54% |
| EPS | -72.82 | 603.52 | 80.70 | 56.19 | -34.80 | 72.49 | 275.06 | 70.55 | 50.89 | 160.34 | -24.68 | -11.19 | 6.41 | 555.36 | 20.77 | 14.66 | 15.43 | 10.00 | 5.63 | 7.96 |
| EPS Diluted | -72.82 | 598.58 | 80.40 | 55.68 | -34.80 | 72.20 | 274.98 | 70.55 | 50.89 | 160.34 | -24.68 | -11.19 | 6.41 | 555.36 | 20.77 | 14.66 | 15.43 | 10.00 | 5.63 | 7.96 |
| Weighted Avg Shares Out | 231.19M | 237.50M | 238.29M | 237.13M | 210.77M | 203.21M | 203.15M | 203.15M | 203.15M | 203.15M | 203.15M | 203.15M | 203.15M | 231.98M | 231.69M | 215.35M | 215.35M | 215.35M | 209.55M | 203.15M |
| Weighted Avg Shares Out (Dil) | 231.19M | 239.46M | 239.19M | 239.27M | 210.77M | 204.02M | 203.15M | 203.15M | 203.15M | 203.15M | 203.15M | 203.15M | 203.15M | 231.98M | 231.69M | 215.35M | 215.35M | 215.35M | 209.55M | 203.15M |
Source: https://incomestatements.info
Category: Stock Reports